Predict Treatment Response for Immunotherapy

Immunotherapy is a promising treatment option for cancer patients. However, the response rate remains low at approximately 20%. Therefore it is crucial to consider predictive biomarkers in patients’ treatment plans to identify those who will respond to immunotherapy.

Tumor Microenvironment Gene Expression Profiling

TODSYHEALTH TME is an RNA-based immune profiling assay that enables the characterization of tumor-immune microenvironment beyond traditional “immune-filtrated” or “non-immune-filtrated” classification, providing insights to facilitate immune-oncology drug development.

  • Profiles > 90 cancer genes to evaluate immunotherapy

  • Proprietary chip-based multiplex qPCR platform

  • Fast turnaround time

  • Accommodates highly degraded specimens with low inputs


  • MHC I Pathway

  • Memory CD8 T Cell

  • Tumor Secretory Cytokines

  • Active CD4 T Cell

  • MDSC

  • Immune Inflammation

  • Active CD8 T Cell

  • Regulatory T Cell

  • Immune Escape Mechanism

  • Memory CD4 T Cell

  • Checkpoint Molecules

Covers TMB, MSI and Immune-related Genes

TODSYSHEALTH® sequences genes involved in immune response and antigen processing and presenting machinery. The mutation statuses of these genes will be considered when recommending immunotherapy. TODSYSHEALTH® covers TMB, MSI and immune-related genes to evaluate the use of immunotherapy.

  • Tumor Mutational Burden (TMB)

  • Microsatellite Instability (MSI)

  • Immune-related Genes

© 2019 Todsyshealth. All rights reserved.